Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219089 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
A Phase 3 study of Hypertension, Diabetes Mellitus, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 839
- Enrollment target
- 2
- Study locations
NCT00219089: Completed Phase 3 study of Hypertension, Diabetes Mellitus, sponsored by Novartis.
NCT00219089 is a Phase 3 study of Hypertension, Diabetes Mellitus that has completed, run by Novartis. The registered enrollment target is 839 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219089, a Phase 3 study of Hypertension, Diabetes Mellitus, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 839 participants
- Enrollment target
- 2
- Study locations
Study Summary
To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus
Conditions Studied
Interventions
- DRUG aliskiren
Study Locations (2)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Other
- - Investigative Centers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
What the finished NCT00219089 record still lists
NCT00219089 is an interventional study that assigns participants to a tested intervention. The registered 839 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Hypertension, Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which aliskiren is the first listed.
NCT00219089 reports a single indexed study location in New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00219089 about?
NCT00219089 is a clinical study titled "A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.". To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus
What is the current status of trial NCT00219089?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 839 participants. The study started on 2004-11. Estimated completion is 2005-08.
What conditions does trial NCT00219089 study?
This clinical trial studies the following conditions: Hypertension, Diabetes Mellitus.
What interventions are being tested in trial NCT00219089?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219089?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219089 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00219089's enrollment target sits among peer trials
839 394th of 2000 higher than 1,607 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia